Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

987 questions in 78 reviews · Haematology

current versions

No studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Ruxolitinib vs best available therapy Health‐related quality of life European Organization for Research and Treatment of Cancer quality of life questionnaire core model. Scores ranges from 0 to 100. Scale from: 0 to 100. · Patients with treating MF Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis (2015) · Cochrane	no estimate extracted	1 study · 96 participants	Low
Ruxolitinib vs best available therapy Reduction in spleen size Magnetic resonance imaging or computed tomography · Patients with treating MF Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis (2015) · Cochrane	RR 41.78 [2.61, 669.75]	1 study · 219 participants	Low
Ruxolitinib vs placebo Progression‐free survival ‐ not measured · Patients with treating MF Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis (2015) · Cochrane	no estimate extracted	1 study · 309 participants	Ungraded
Ruxolitinib vs placebo Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis (2015) · Cochrane	RR 9.74 [2.32, 40.96]	1 study · 306 participants	Low
Ruxolitinib vs placebo Safety (AE, adverse drug reaction): neutropenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis (2015) · Cochrane	RR 3.57 [1.02, 12.55]	1 study · 306 participants	Low
Ruxolitinib vs placebo Health‐related quality of life Patients that achieved a reduction of 50% or more in the total MF Symptom Assessment Form · Patients with treating MF Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis (2015) · Cochrane	RR 8.82 [4.4, 17.69]	1 study · 309 participants	Low
Ruxolitinib vs placebo Reduction in spleen size Magnetic resonance imaging or computed tomography · Patients with treating MF Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis (2015) · Cochrane	RR 64.58 [9.08, 459.56]	1 study · 309 participants	Low
Ruxolitinib vs best available therapy Overall survival (number of deaths at · Patients with treating MF Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis (2015) · Cochrane	HR 0.7 [0.2, 2.47]	1 study · 219 participants	Low
Ruxolitinib vs best available therapy Progression Free Survival (number of patients who had progression at · Patients with treating MF Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis (2015) · Cochrane	HR 0.81 [0.47, 1.39]	1 study · 219 participants	Low
Ruxolitinib vs best available therapy Safety (AE, adverse drug reaction): anemia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis (2015) · Cochrane	RR 1.35 [0.91, 1.99]	1 study · 219 participants	Low
Intervention NR Mortality at 2 years · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	HR 0.9 [0.84, 0.96]	12 studies · 5976 participants	High
Intervention NR Complete remission · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	RR 0.97 [0.92, 1.03]	8 studies · 2411 participants	Moderate
Intervention NR Death on induction therapy · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	RR 1.1 [0.88, 1.38]	5 studies · 2055 participants	Moderate
Intervention NR Relapse · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	RR 0.99 [0.8, 1.22]	3 studies · 328 participants	Moderate
Intervention NR Grade 3/4 cardiotoxicity · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	RR 0.67 [0.11, 3.88]	1 study · 160 participants	Low
Intervention NR Quality of life not reported · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	no estimate extracted	0 participants	Ungraded
Intervention NR Mortality at 2 years not reported · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	no estimate extracted	0 participants	Ungraded
Intervention NR Mortality/relapse at 2 years · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	HR 0.62 [0.34, 1.14]	1 study · 63 participants	Low
Intervention NR Complete remission · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	RR 1.28 [1.03, 1.59]	2 studies · 187 participants	Low
Intervention NR Death on induction therapy not reported · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	no estimate extracted	0 participants	Ungraded
Intervention NR Relapse not reported · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	no estimate extracted	0 participants	Ungraded
Intervention NR Mortality/relapse at 2 years · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	HR 0.88 [0.81, 0.96]	8 studies · 3070 participants	Moderate
Intervention NR Grade 3/4 cardiotoxicity · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	RR 0.31 [0.01, 7.39]	1 study · 100 participants	Very low
Intervention NR Quality of life not reported · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	no estimate extracted	0 participants	Ungraded
Intervention NR Mortality at 2 years not reported · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	no estimate extracted	0 participants	Ungraded
Intervention NR Mortality/relapse at 2 years · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	HR 1.25 [0.83, 1.88]	1 study · 155 participants	Low
Intervention NR Complete remission · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	RR 1.04 [0.96, 1.13]	2 studies · 964 participants	Low
Intervention NR Death on induction therapy · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	RR 0.75 [0.5, 1.13]	2 studies · 964 participants	Moderate
Intervention NR Relapse not reported · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	no estimate extracted	0 participants	Ungraded
Intervention NR Grade 3/4 cardiotoxicity not reported · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	no estimate extracted	0 participants	Ungraded
Intervention NR Quality of life not reported · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	no estimate extracted	0 participants	Ungraded
Intervention NR Complete remission · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	RR 1.04 [1.01, 1.07]	18 studies · 6692 participants	Moderate
Intervention NR Death on induction therapy · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	RR 1.18 [1.01, 1.36]	14 studies · 6349 participants	Moderate
Intervention NR Relapse · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	RR 0.88 [0.8, 0.98]	4 studies · 1091 participants	Moderate
Intervention NR Grade 3/4 cardiotoxicity · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	RR 0.98 [0.7, 1.37]	6 studies · 2795 participants	Moderate
Intervention NR Quality of life not reported · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	no estimate extracted	0 participants	Ungraded
Intervention NR Mortality at 2 years · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	HR 0.98 [0.89, 1.08]	6 studies · 2171 participants	High
Intervention NR Mortality/relapse at 2 years · patients with newly diagnosed AML The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed… (2015) · Cochrane	HR 0.88 [0.7, 1.1]	4 studies · 249 participants	Low
Intervention NR Overall survival · individuals with HL Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma (2015) · Cochrane	no estimate extracted	3 studies · 1480 participants	Very low
Intervention NR PFS: relapse or death · individuals with HL Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma (2015) · Cochrane	HR 2.38 [1.62, 3.5]	3 studies · 1480 participants	Moderate
Intervention NR Adverse events · individuals with HL Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma (2015) · Cochrane	RR 0.91 [0.54, 1.53]	1 study · 160 participants	Very low
Intervention NR Quality of life · individuals with HL Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma (2015) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Treatment related mortality · individuals with HL Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma (2015) · Cochrane	no estimate extracted	NR	No studies
Plerixafor vs placebo Mortality (12 months) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple… Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation… (2015) · Cochrane	RR 1 [0.59, 1.69]	2 studies · 600 participants	Moderate
Plerixafor vs placebo Quality of life · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple… Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation… (2015) · Cochrane	no estimate extracted	NR	No studies
Plerixafor vs placebo Progression‐free survival · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple… Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation… (2015) · Cochrane	no estimate extracted	NR	No studies
Plerixafor vs placebo Time to engraftment · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple… Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation… (2015) · Cochrane	no estimate extracted	NR	No studies
Plerixafor vs placebo Number of transplanted participants · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple… Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation… (2015) · Cochrane	no estimate extracted	NR	No studies
Plerixafor vs placebo Successful stem cell collection · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple… Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation… (2015) · Cochrane	RR 2.42 [1.98, 2.96]	2 studies · 600 participants	High
Plerixafor vs placebo Adverse events (during stem cell mobilisation and collection) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple… Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation… (2015) · Cochrane	RR 1.02 [0.99, 1.06]	2 studies · 593 participants	High